Mirum Pharmaceuticals, Inc. Payments to Acquire Businesses, Gross
Mirum Pharmaceuticals, Inc. (MIRM) reported Payments to Acquire Businesses, Gross of $2.60 million for the 1-month period ending 2022-05-31, per its 10-Q filed 2023-05-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesGross · last filed 2023-05-04
- 2022-05-31: Payments to Acquire Businesses, Gross 1 month $2.60M.
| Period end | Payments to Acquire Businesses, Gross 1 month |
|---|---|
| 2022-05-31 | $2.60M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |